Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19/BCMA CAR-T for Relapsed/Refractory POEMS Syndrome
NCT03879382Phase 1Unknown
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Feb 2019
- Primary completion
- Aug 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 + anti-BCMA CAR-T cells in POEMS syndrome (POEMS), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Safety measured by occurrence of study related adverse effects at 6 months. Status: unknown.
02
Drugs
anti-CD19 + anti-BCMA CAR-T cells
03
Conditions
POEMS syndrome (POEMS)
Beyond the preview
Go deeper on NCT03879382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879382.